Summary: Pharmexa and VaxOnco of South Korea have entered into an agreement
whereby VaxOnco will acquire all shares of Pharmexa-Epimmune (Pharmexa Inc.)
and will thus assume all rights and responsibilities relating to the patent
portfolio of Pharmexa-Epimmune.
VaxOnco Inc, a Korean company specializing in peptide based vaccines, has
acquired Pharmexa-Epimmune (Pharmexa Inc.) by the purchase of all outstanding
shares from Pharmexa A/S for €440,000. VaxOnco will thus assume all rights and
responsibilities relating to the Pharmexa-Epimmune patent portfolio.
Dr. Achim Kaufhold, Pharmexa´s CEO, says “In line with our cost-cutting
activities and our new strategic direction, Pharmexa A/S discontinued
operations at our Pharmexa-Epimmune subsidiary in San Diego at the end of last
year. The sale of Pharmexa-Epimmune to VaxOnco completes that process and will
result in substantial savings to Pharmexa A/S in the future.”
Hørsholm, April 24, 2009
Achim Kaufhold
Chief Executive Officer
Additional information:
Claude Mikkelsen, Senior Vice President, Finance & Investor Relations, tel. +45
4516 2525 or +45 4060 2558
Achim Kaufhold, Chief Executive Officer, tel +45 4516 2525
